pretickt

Is LH a good stock to buy?

Labcorp Holdings Inc. · end-of-day data as of Nov 13, 2026

Labcorp
LH · $30.08B
$370.48-0.5%
Nov 13, 2026 · close
$300$350SepOctNov9:3016:003 months +15.2%Nov 13 · close
▲ 7
  • ConsensusBuy · 18
  • FCF yield+4.3%
  • News
  • Trendbullish
  • MAs4 of 4
  • MACD1.03
  • Sector▲ +15.9%
Neutral
  • Earnings in95d
  • P/E30.4x
  • RSI69
  • Support-13.4%
  • Off 52w high-1.2%
  • Volume0.6x
  • Bollingerupper half
  • P/E vs sector-5.7%
  • PT$373.55 +0.8%
  • 52w range$245–$375
  • ATR+2.6%
  • Off ATH-1.2%
▼ 2
  • P/E vs own+26.6%
  • Insiders-$2.2M

Updates with the 15-min delayed price. Not a forecast or investment advice.

Is Labcorp a good stock to buy?

Labcorp is strong on 3 of the 4 questions about the business. The price is about usual: 30.4 times its earnings, near its 3-year median of 27.5 (Nov 13, 2026). pretickt does not say whether to buy or sell.

  1. Demand steady
  2. Economics profits growing
  3. Execution delivers
  4. Fragility sturdy
  5. Price about usual
DemandDo people want more of what it sells?steady

LH sales growth revenue growth

+1%a year, for the last 3 years

Labcorp's sales grew 1% a year for 3 years, to $13.95B in fiscal 2025.

LH analysts' forecast revenue estimates

+6%the sales they expect next fiscal year, on the last

Analysts expect Labcorp's sales to grow 6% to $14.83B in fiscal 2026 (8 analysts).

LH competitors

pretickt analysis+6%its sales in 12 months, on a year before

Labcorp's sales grew 6% in the 12 months to Sep 30, 2026, faster than Illumina (+6%), slower than Quest Diagnostics (+9%), IQVIA (+9%) and Mettler-Toledo (+7%).

EconomicsDoes it make good money?profits growing

LH cash generated free cash flow

$1.29Bcash left after investing, last 12 months

Labcorp generated $1.29B of free cash flow in the 12 months to Sep 30, 2026, more than its reported profit.

LH profit per share

+18%in its last fiscal year

Labcorp's earnings per share grew 18% in fiscal 2025, to $10.46.

ExecutionDoes it deliver what it promises?delivers

LH earnings vs estimates

8 of 8quarters above the analysts' estimate

Labcorp beat the analysts' profit estimate in each of its last 8 quarters, the latest on Oct 28, 2026.

LH insider selling

-$11.65Msold, net, by its executives in 12 months

Labcorp's executives and directors sold a net $11.65M of shares in the 12 months to Nov 13, 2026; none bought.

LH number of employees

+1%more people in a year

Labcorp had 71,000 employees at the end of fiscal 2025, 1% more than a year before.

LH CEO pay

$18.34Mfor fiscal 2025, 77% of it in stock and options

Labcorp paid its CEO $18.34M for fiscal 2025, 77% of it in stock and options.

Fragility risksCould something break it?sturdy

LH financial health Altman Z-score

3.6Altman Z-score, safe above 3

Labcorp's Altman Z-score is 3.6 (Nov 13, 2026), above 3, where the safe zone starts.

LH quality checks Piotroski score

7 of 9checks passed

Labcorp passes 7 of the 9 Piotroski checks in the 12 months to Sep 30, 2026; it misses on the current ratio and gross margin.

LH in past recessions

pretickt analysis+4%its sales in the worst one

Labcorp's sales grew through each of the last 2 US recessions (2008–09 and 2020).

Price valuationIs the price reasonable?about usual

LH price vs profit P/E ratio

30.4×a year's earnings

Labcorp's P/E ratio is 30.4 (Nov 13, 2026), near its 3-year median of 27.5.

LH price vs competitors

pretickt analysis30.4×a year's earnings, against its competitors

Investors pay 30.4 times Labcorp's earnings (Nov 13, 2026), more than for Quest Diagnostics (25.9), less than for Mettler-Toledo (37.7), Illumina (35.6) and IQVIA (32.2).

LH analysts' target price target

+1%to their average target

Analysts' average price target for Labcorp is $374, 1% above the Nov 13, 2026 close of $370.48.

LH growth priced in fair value

pretickt analysis+9%a year, for ten years, to be worth the price

At $370.48 a share, Labcorp's free cash flow must grow about 9% a year for ten years to be worth the price (Nov 13, 2026).

What is Labcorp's P/E ratio?

Labcorp's P/E ratio is 30.4 (Nov 13, 2026), near its 3-year median of 27.5. Investors pay 30.4 times Labcorp's earnings (Nov 13, 2026), more than for Quest Diagnostics (25.9), less than for Mettler-Toledo (37.7), Illumina (35.6) and IQVIA (32.2).

Who are Labcorp's biggest competitors?

pretickt compares Labcorp with Illumina, Quest Diagnostics, Mettler-Toledo and IQVIA. Labcorp's sales grew 6% in the 12 months to Sep 30, 2026, faster than Illumina (+6%), slower than Quest Diagnostics (+9%), IQVIA (+9%) and Mettler-Toledo (+7%).

Are insiders selling Labcorp stock?

Labcorp's executives and directors sold a net $11.65M of shares in the 12 months to Nov 13, 2026; none bought.

How many employees does Labcorp have?

Labcorp had 71,000 employees at the end of fiscal 2025, 1% more than a year before.

From the companies' statements (FMP), their filings read by pretickt, the analysts and the insiders, as of Nov 13, 2026. Each card says what a fact means for its question, never what to do with the stock: for information only, not investment advice.